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Medicinal inorganic chemistry has been stimulating largely by the success of the anticancer drug, cisplatin. Various metal
complexes are currently used as therapeutic agents (e.g., Pt, Au, and Ru) in the treatment of malignant diseases, including
several types of cancers. Understanding the mechanism of action of these metal-based drugs is for the design of more eﬀective
drugs. Proteomic approaches combined with other biochemical methods can provide comprehensive understanding of responses
that are involved in metal-based anticancer drugs-induced cell death, including insights into cytotoxic eﬀects of metal-based
anticancerdrugs,correlationofproteinalterationstodrugtargets,andpredictionofdrugresistanceandtoxicity.Thisinformation,
when coupled with clinical data, can provide rational basses for the future design and modiﬁcation of present used metal-based
anticancer drugs.
Copyright © 2008 Y. Wang and J.-F. Chiu. This is an open access article distributed under the Creative Commons Attribution
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1. METAL-BASED ANTICANCER DRUGS
Medicinal applications of metal complexes as therapeutic
drugs have a more than 5000-year history [1]. Since
the discovery of the anticancer activity of cisplatin by
Shimizu and Rosenberg 35 years ago, there has been a
rapid expansion in research to ﬁnd new, more eﬀective
metal-based anticancer drugs [2]. The major classes of
metal-based anticancer drugs include platinum (II), gold
(I) and gold (III), metalloporphyrin, ruthenium (II) and
ruthenium (III), bismuth (III), rhenium (I), and copper (II)
compounds.
1.1. Platinum(II)anticancerdrugs
Cisplatin represents one of the most potent drugs available
in the cancer chemotherapy for several solid tumors, such
as testicular, ovarian, bladder, and neck cancers [3]. It
is generally believed that cisplatin exhibited its anticancer
eﬀects through preferentially binding to quinine N-7 of
DNA, and then cause DNA damage speciﬁcally in cancer
cells, subsequently leading to cell death [4]. After successes
achieved with platinum complexes, there is a tremendous
increase in the search for platinum complexes with diﬀerent
ligands that might produce more speciﬁc anticancer eﬀects.
Some of these platinum-based drugs have been approved
by the Food and Drug Administration (FDA), including
carboplatin for the treatment of ovarian cancer [5, 6],
oxaliplatin for metastatic colorectal cancer [7, 8], satraplatin
for hormone-refractory prostate cancer [9], and picoplatin
f o rs m a l l - c e l ll u n gc a n c e r[ 10].
Transplatinum compounds follow diﬀerent patterns of
cell killing in comparison to cisplatinum, thus giving a
reason for optimism in their development as a new class
of platinum-based anticancer drugs [11]. The initial report
of anticancer properties of a dinuclear platinum complex in
1988 started a new paradigm in platinum-based chemother-
apy. Several multinuclear platinum complexes have entered
clinical trials in recent years, with varying results [12, 13].
The major limitations of cisplatin and other platinum
anticancer drugs are related to drug resistance and their
side eﬀects, including nephrotoxicity, neurotoxicity, and
emetogensis [14]. Resistance to cisplatin is multifactorial,
most cases consist of mechanisms limiting the formation of
DNAadductsoroperatingdownstreamofthecisplatin-DNA
interaction to promote cell survival [15].2 Metal-Based Drugs
1.2. Gold(I)andgold(III)anticancercomplexes
Gold (I) complexes had been used for the treatment of
arthritis some decades ago, but most of them disappeared
fromthedrugmarketbecauseofintolerablesideeﬀects,such
as gastrointestinal adverse reactions, nephrotoxicity, and
haematological reactions. However, the design and testing
of gold complexes, especially gold (III) complexes with
anticancer activity begin to be intensively pursued in the
past few years. The potential use of gold (III) complexes
as anticancer drugs were based on three rationales [16–
18]: (a) analogies between square planar complexes of both
platinum (II) and gold (III) are d
8 ions; (b) analogy to the
immunomodulatory eﬀects of gold (I) antiarthritic agents;
and (c) complexation of gold (I) and gold (III) with known
anticancer agents to form new compounds with enhanced
activity. Buckley et al. ﬁrst reported some organogold (III)
complexesendowedwithsigniﬁcantcytotoxicandanticancer
properties [19]. During the past decades, various gold
(III) complexes with suﬃcient stability in the physiological
environmenthavebeensynthesizedandevaluatedforinvitro
anticancer properties. Some of these gold (III) complexes
turned out to exhibit relevant cytotoxic eﬀects in vitro and
were the subject of further biochemical and pharmacological
investigations [20–33]. Our previous ﬁndings showed that
gold (III) mesotetraarylporphyrin 1a was stable against
demetallation in physiological conditions and exhibited
higher cytotoxicity than cisplatin against a panel of human
cancer cell lines [34–37]. The major limitation of gold
(III) complexes is that few exhibit good stability under
physiological conditions, due to the reduction of gold (III)
to gold (I) [38]. However, low cisplatin cross resistance has
been observed in gold complexes [39]. There is therefore
considerable interest in the development of tumor-selective
and stable gold anticancer drugs.
1.3. Metalloporphyrindrugs
Metalloporphyrin drugs are new class of antioxidant enzyme
mimetics with novel structure: a metal in the center of
porphyrin ligand. Metalloporphyrins (e.g., MnTBAP) have
previously been used to inhibit age-related oxidative damage
in myocardium of mice that are lacking mitochondrial
enzyme manganese superoxide dismutase [40]. Afterwards,
metalloporphyrin drugs began to be used as photodynamic
therapy agents for certain solid tumors [41]. Photodynamic
therapy is based on the concept that porphyrins are known
to be rapidly and preferentially taken up by the tumor
cells with higher intakes of lipoproteins [42, 43]. When
such photosensitizers are irradiated with an appropriate
wavelength of visible or near infrared (NIR) light, the
excited molecules can transfer their energy to molecular
oxygen in the surroundings, which is normally in its triplet
ground state. This results in the formation of cytotoxic
reactive oxygen species (ROSs), particularly singlet oxygen
[44]. ROSs are responsible for oxidizing various cellular
compartments including plasma, mitochondrial, lysosomal,
and nuclear membranes, resulting in irreversible damage of
tumor [34, 44]. Therefore, under appropriate conditions,
photodynamic therapy oﬀers the advantage of an eﬀective
and selective method of destroying diseased tissues without
damaging adjacent healthy cells [42, 43].
Since the approval of Photofrin by FDA for chemother-
apy [45], porphyrin derivatives with diﬀerent metal in the
center of the molecule have been widely used as photosen-
sitizers for photodynamic therapy in the treatment of can-
cer, including chlorophyllin copper complex as superoxide
dismutase mimics [46, 47], FeTBAP and MnTBAP [48, 49],
ZnTBAP [50], motexaﬁn gadolinium (MGd) [51]. Diﬀerent
modes of actions have been suggested for diﬀerent kinds
of metalloporphyrins. For example, MGd has been shown
to inhibit heme oxygenase-1 (HO-1) activity that results in
inactivation of the antiapoptotic properties of the products
of HO-1 [51]. While FeTBAP and MnTBAP have been
reported tobe superoxideanionscavengers[48].MGdisalso
an active inhibitor of cytochrome P450 enzymes, although
with a lower potency than that exhibited for inhibition of
HO-1.
1.4. Othermetal-basedanticancerdrugs
In recent years, other approaches in the search for new,
metal-based anticancer agents are to examine complexes
that contain other transition metals. In the design of these
new drugs, octahedral ruthenium (II) and ruthenium (III)
complexes have shown antineoplastic properties on a num-
ber of experimental tumors. Tetraammine-, pentaammine-,
heterocycle-, and dimethylsulfoxide-coordinated ruthenium
complexes have been synthesized and shown high aﬃnity
for nitrogen donor ligands in vitro and as a result exhibit
anticancer action in vivo [52–54]. Other transition metals
have been used as anticancer drugs, including bismuth (III)
labeled antibodies for systemic radioimmunotherapy [55,
56], rhenium (I) complexes as DNA-binding agents [57],
(MTR)2Zn2+ complexthatinducescancercelldeathbybind-
ing to chromatin [58], and Cu2+ compound chlorophyllin
initiated apoptosis in human colon cancer cells through
caspase-8 and apoptosis-inducing factor (AIF) activation in
a cytochrome c-independent manner [46].
2. PROTEOMICS
2.1. Introductiontoproteomics
Theproteomeisdeﬁnedasallexpressedproteincomplement
of a cell, organ or organism, and it includes all isoforms and
posttranslationalvariants.Proteomictechnology,ﬁrstcoined
in 1995 [59], attempts to separate, identify, and characterize
a global set of proteins in an eﬀort to provide infor-
mation about protein abundance, location, modiﬁcation,
and protein-protein interaction in the proteome of a given
biological system [59, 60]. This postgenomic technology
provides a direct measurement of the presence and relative
abundance of proteins, and reveals the consequence of pro-
tein functioning in establishing the biological phenotype of
organisms in diﬀerent states. By studying interrelationships
of protein expressions and modiﬁcations in health and
disease or drug treatment, proteomics contributes importantY. Wang and J.-F. Chiu 3
insights into determining the pathophysiological basis of
disease [61], validating drug targets [62], and illustrating
drug action [63], toxicity, and side eﬀects [64].
2.2. Technologicalplatforms
In the ﬁeld of proteomics, several well-established methods
persist as means to resolve and analyze complex mixtures
of proteins derived from cells and tissues. Currently, the
most commonly used proteomic platforms include two-
dimensional gel electrophoresis (2DE) and protein chip
arrays, isotope-coded aﬃnity tages (ICATs), and immo-
bilized metal aﬃnity chromatography (IMAC) (Table 1).
These technological platforms are most often incorporated
with matrix-assisted laser desorption/ionization time of
ﬂight(MALDI-TOF)[65],surfaceenhancedlaserdesorption
ionization time of ﬂight (SELDI-TOF) [66], electrospray
ionization (ESI) [67], and/or tandem mass spectrometry
(MS/MS). In addition, inductively coupled plasma (ICP)
mass spectrometry has also been applied in proteomic-based
research of drug discovery [68].
3. POTENTIAL APPLICATIONS OF PROTEOMICS
IN ILLUSTRATING METAL-BASED DRUG
DEVELOPMENT AND DISCOVERY
Ever since the initial discovery of the anticancer activity of
cisplatin, major eﬀorts have been devoted to elucidate the
biochemical mechanisms of anticancer activities of metal-
based drugs to facilitate rational design of novel metal-based
drugswithbetterpharmacologicalproﬁles.Acomprehensive
understanding of the molecular action mechanisms, which
aretriggeredbymetal-baseddrugstokillcancercellscanlead
to the design of more eﬀective anticancer drugs, as well as to
provide new therapeutic strategies based on the molecular
activity of metal-based drug activity.
3.1. Targetdiscoveryandvalidation
Target discovery, which involves the identiﬁcation and early
validation of disease-associated targets, is an essential ﬁrst
step in the drug discovery pipeline [81]. Indeed, the drive
to determine protein function has been stimulated, both in
industryandacademia,bythehumangenomeandproteome
projects in progress. Proteomics, the study of cellular protein
expression, is an evolving technology platform that has the
potential to identify novel proteins involved in key biological
processes in cells. These proteins may serve as potential drug
targets. Proteomics thus holds great promise as a powerful
technique for drug target discovery. It must be pointed
out, however, that numerous drug-targeted proteins are
membrane-bound proteins, for example, receptors and ion
channels. These proteins may not be amenable for study by
proteomics due to their poor solubility and low abundance,
and thus they are disproportionally represented in proteome
proﬁles [82]. Up to date, only a fraction of putative drug tar-
gets has been identiﬁed by proteomic approaches, including
the volume-sensitive organic osmolyte/anion channel as key
elementsoftumordevelopment,migration,andinvasiveness
[83], and integrin alpha-4 as a molecular target of oxidative
stress [84].
Studying protein expression proﬁling of drug-treatment
leads to the identiﬁcation of a number of drug-speciﬁc
targets both in vivo and in vitro. Using HPLC-MALDI-TOF
MS, Hasinoﬀ et al. have identiﬁed topoisomerase IIα con-
tained at least ﬁve free cysteins (170, 216, 300, 392, and 405)
and two disulﬁde-bonded cyteine pairs (427-455 and 997-
1008) [85]. Cisplatin was found to antagonize the formation
of a ﬂuorescence adduct between topoisomeraser IIα and the
sulfhydryl-reactive maleimide reagent 10-(2,5-dihydro-2,5-
dioxo-1H-pyrrol-1-yl)-9-methoxy-3-oxo-3H-naphtho[2,1-
b]pyran-2-carboxylic acid methyl ester (ThioGlo-1). Based
on these results, the authors suggested that topoisomeraser
IIα cysteines may be possible sites responsible for the
inhibition of the catalytic activity of topoisomeraser IIα
observed in the presence of cisplatin, and topoisomeraser
IIα cysteins and DNA as targets responsible for cisplatin-
induced inhibition of topoisomeraser IIα [85]. Besides,
mitochondrial proteins, especially ATP synthase-beta
subunit, have been reported to be key proteins that serve
as primary target of manganese porphyrin [MnTnHex-
2-PyP(5+)] treatment during renal ischemia/reperfusion
i n j u r yb yp r o t e o m i cs t u d y[ 86].
ICP MS coupled with capillary electrophoresis (CE)
has been used in the identiﬁcation, characterization, and
determination of diﬀerent chemical species of an element
in complex biological systems, that is, the impetus of
biochemical speciation analysis [87, 88]. Polec-Pawlak et
al. have used this approach to study the platinum group
metallodrug-protein binding aiming to characterize the
interactions between cancer-inhibiting metal complexes and
serum transport proteins [89]. Such binding does not
only regulate the uptake and accumulation of the drug in
tumor tissue but also determines its overall distribution and
exertion and diﬀerences in eﬃcacy, activity, and toxicity [90,
91]. Their study provides clear evidence that a ruthenium
(III) complex [trans-tetrachlorobis(1H-indazole)ruthenate
(III)] (KP1019) preferentially binds toward albumin whose
adduct is a dominating protein-bound species of ruthenium
[89].
3.2. Validationofdrugtoxicityandresistance
Insights into toxic responses are an asset for the interpre-
tation of adverse drug eﬀects and contribution to accurate
riskassessmentforhumans.Proteomicsincombinationwith
combinatorial chemistry and high-throughput screening can
help to bring forward validating toxicity and resistance of
an unprecedented number of potential lead compounds
[92]. Beneﬁts can be expected in optimized clinical trials
based on the availability of biologically relevant markers
of drug eﬃcacy and safety. Proteomics has demonstrated
proof-of-concept in toxicology as shown by a number of
successful applications in mechanistic toxicology and lead
selection. Proteomic studies of liver toxicity have been
carried out with thioacetamide [93] and ethanol [64]. Other
researches have studied nephrotoxicity of cyclosporine A by
proteomic approaches [94, 95]a n dr e p o r t e dap r o f o u n d4 Metal-Based Drugs
Table 1: Major technological platforms in proteomics.
Technique 2DE (Two-dimensional gel
electrophoresis) SELDI-TOF MS ICAT (Isotope-coded
aﬃnity tags)
IMAC (Immobilized metal
aﬃnity chromatography)
Principles
2DE separates protein
mixtures by their isoelectric
points and molecular
weights, proteins can be
identiﬁed by MALDI-TOF
MS through enzyme
digestion
This technique employs
protein chip separates
protein mixtures by
diﬀerent surface binding
aﬃnity and molecular
weights, and roughly
identiﬁes proteins through
SELDI-TOF MS
ICAT separates proteins by
chemical labeling and
relative abundance, and
then obtains protein
identiﬁcation through ESI
MS/MS
IMAC is a powerful protein
fractionation method used
to enrich metal-associated
proteins and peptides,
proteins and peptides can
be determined by ESI
MS/MS
Remarks
Suitable for whole
proteome or speciﬁc
pre-fractioned proteomes,
detect large quantity of
proteins in a single run, not
suitable for low abundant
proteins, aﬀected by
posttranslational
modiﬁcations
Simple preparation
procedures, sensitive
detection limit, small
sample requirement,
signiﬁcant results, wide
detection range in
molecular weight, modiﬁed
by diﬀerent surface
aﬃnities
Biotinylated tags labeling
before analysis; suitable for
low abundant proteins; not
suitable for post
translational modiﬁed
proteins; more automated
Enrich metal-associated
proteins and peptides, easy
regeneration, longevity and
stability to proteolytic
degradation, have to be
facilitated by other
separation methods,
suitable for
posttranslational
modiﬁcation
Potential
applications
Study drug-induced
cellular signaling pathway
in a global scale [35, 69]
Identiﬁcation of drug
targets [70]
Identiﬁcation of drug
targets [70]
Screen drug candidates
[72, 73]
Receptome proﬁling
[75, 76]
Mapping of
phosphoproteomes [77, 78]
and metalloproteomes
[79, 80]
Study of drug toxicity and
side eﬀects [71]
Study of protein-drug
interactions [74]
downregulation of the calcium binding protein calbindin
D28 responsible for cyclosporine A-induced kidney toxicity.
However, this technology-driven acceleration in drug dis-
covery moves the bottlenecks in drug development to the
downstream, which is the improvement in the selection of
patient populations for clinical trials.
Proteomic approaches have been used to identify the
underlying mechanisms for cisplatin resistance [96]. In this
study, the authors used cervix squamous cell carcinoma
cell line A431 and its cisplatin-resistant subline, A431/Pt
as model system. The identiﬁed diﬀerentially expressed
proteins can be classiﬁed into several groups, including
molecular chaperones (e.g., heat-shock protein HSP60,
HSP90, and HSC71), Ca2+-binding proteins (e.g., calmod-
ulinandcalumenin),proteinsinvolvedindrugdetoxiﬁcation
(e.g., peroxiredoxin 2 and 6, and glutathione-S-transferase),
antiapoptotic proteins (e.g., 14-3-3 switched on in cisplatin-
exposed cells) and ion channels (e.g., voltage-dependent
anion channel 1, voltage-dependent anion-selective chan-
nel).Besidesthis,proteomeproﬁleofcisplatinsensitiveovar-
ian cell line IGROV1 and its cisplatin-resistant counterpart
IGROV1-R10 have been compared aiming to ﬁnd any pro-
tein markers or to establish new therapeutic strategies [97,
98]. Increased expression of cytokeratin 8 and cytokeratin 18
was considered to play a role in acquired chemoresistance
of IGROV1-R10 cancer cell line to cisplatin [97, 98].
Cytokeratin 8 and cytokeratin 18 have been implicated
in resistance to TNF-α-induced apoptosis by binding the
cytoplasmic domain of tumor necrosis factor receptor 1
[69, 99]. Moreover, human nasopharyngeal carcinoma cells
deﬁcient for cytokeratin 8 were more sensitive to cisplatin-
induced apoptosis [100].
In addition, acquired and intrinsic cellular drug resis-
tances are multifactorial processes, involving induction of
drug detoxifying mechanisms, quantitative and qualitative
modiﬁcation of drug targets, cell cycle arrest, regulation of
DNA replication or reparation mechanisms, modulation of
apoptosis, and other mechanisms [101, 102]. Global exami-
nation of the glycoproteomes of the cisplatin-resistant ovar-
ian cancer cell line IGROV-1/CP using shotgun glycopeptide
capture approach coupled with MS has been used to study
cisplatin resistance [103]. In this approach, glycopeptides
derived from glycoproteins are enriched by selective capture
onto a solid support using hydrazide chemistry followed by
enzymatic release of the peptides and subsequent analysis by
MS/MS.This method improves solubility oflargemembrane
proteins and exposes all of the glycosylation sites to ensure
equal accessibility to capture reagents. Stewartet al. also used
isotope-coded aﬃnity tags (ICATs) integrated with mRNA
expression levels to study cisplatin resistance in ovarian
cancer cells [104]. Their study identiﬁed three pathways
in Panther database (http://www.pantherdb.org/) that wereY. Wang and J.-F. Chiu 5
signiﬁcantly (p<. 05) upregulated in cisplatin-sensitive cells,
including glycolysis, interleukin signaling pathway, and PI 3-
kinase pathway [104].
3.3. Mappingdrugactionmechanisms
An understanding of protein function within the context
of complex cellular networks is required to facilitate the
discovery of novel drug targets and, subsequently, new thera-
pies directed against them. Proteomics oﬀers comprehensive
monitoring of protein alterations at molecular level upon
drug treatments. Being the basic biochemical mode of drug
activities, drug action mechanism should be better under-
stood to provide valuable insights into drug modiﬁcation
and new drug development [34, 105]. Successful examples
in drug mechanism study using proteomics include the
illustration of insulin-like growth factor-binding protein-
6-induced sublethal hydrogen peroxide stress in human
diploid ﬁbroblasts cells [106]. By using ESI MS/MS, Kanski
et al. have applied proteomic analysis of protein nitration in
agingskeletalmuscleandidentiﬁednitrotyrosine-containing
sequences in vivo [107].
In our previous study, we have used 2DE-based pro-
teomic technology to compare the protein proﬁle of human
nasopharyngeal carcinoma SUNE1 cell line treated with gold
(III) porphyrin 1a, and a number of diﬀerentially expressed
proteins were identiﬁed [35]. These proteins can be classiﬁed
into several categories based on their major biological func-
tions, including cellular structural proteins, stress-related
and chaperone proteins, proteins involved in ROS, enzyme
proteins and translation factors, proteins that mediate cell
death and survival signaling, and proteins that participate in
the internal degradation system [35]. Among these proteins,
oneofthesigniﬁcantincreasedproteinsisvoltage-dependent
anion channel 1 (VDAC 1). VDAC 1 is a mitochondrial
outer membrane channel protein, which functions as the
pathway for the movement of various substances in and
out of the mitochondria [108]. It is considered to be a
component of the permeability transition pore oligoprotein
complex that plays a role in the permeability transition
[109, 110]. VDAC 1 also plays an essential role in Bax/Bak-
induced apoptotic mitochondrial changes in the process
of mammalian cell death [111–113]. In this process, the
proapoptotic proteins Bax and Bak bind to VDAC 1, and
enhanceitspermeabilitysothatcytochromecpassesthrough
the channel and releases to cytoplasm [111–113]. Our data
on VDAC 1 upregulation [35] and Bax overexpression [37]
suggest that gold (III) porphyrin 1a may induce cell death
via the mitochondria-mediated apoptosis pathway. Further
functional studies revealed that gold (III) porphyrin 1a
caused depletion of mitochondrial transmembrane potential
(ΔΨm) soon after uptake with suppression of Bcl-2, and
activation of caspase 9 and caspase 3 [34]. Taken together,
these results suggested that mitochondria are the primary
target of gold (III) porphyrin 1a.
Quantitative proteomic analysis on other metal-based
anticancer drugs has also been pursuit. Schmidt et al. have
used nano-LC coupled oﬄine MALDI-TOF/TOF-MS to
study cisplatin-induced apoptosis in Jurkat T cells [114].
Their results showed that this method is more accurate than
the commonly used online LC-ESI-MS.
4. CONCLUSION AND FUTURE PROSPECTS
Thepot entialvalueofpr ot eomicsinmetal-baseddrugdev el-
opment, especially in mapping drug action mechanisms, has
been demonstrated in many successful examples. Proteomic
approaches have been recognized as promising techniques
that can facilitate the systematic characterization of a drug
targets’ physiology, thereby helping to reduce the typically
high attrition rates in discovery projects, and improving
the overall eﬃciency of pharmaceutical research processes.
However, at present stage, the bottleneck for taking full
advantage of this new experimental technology is the rapidly
growing volumes of automatically produced biological data,
and technical challenges with regards to sampling, tumor
heterogeneity, and lack of standardized methodologies. In
addition, to complement the limitation of current proteomic
technology, systematic biological and pharmaceutical studies
should be integrated with proteomics to better serve the
purpose of illustrating the action mechanism of drugs
and thus contribute to the success in metal-based drug
development.
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